Antibodies News and Research

RSS

Advancement of ultrasound theranostic techniques in medicine and biology

Announcing a new article publication for BIO Integration journal. In this editorial, Co-Editor-in-Chief, Pingtong Huang considers an integrated approach to ultrasound imaging in medicine and biology.

19 Oct 2020

Sinopharm's candidate SARS-CoV-2 vaccine BBIBP-CorV shows promise in clinical trials

Researchers in China have conducted a phase 1/2 trial demonstrating the safety, tolerability, and immunogenicity of a candidate vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the current coronavirus disease 2019 (COVID-19) pandemic.

18 Oct 2020

Comparative analysis reveals common vulnerabilities across coronaviruses

Three lethal human respiratory syndromes associated with coronavirus (CoV) infections have emerged in the past two decades. They are severe acute respiratory syndrome (SARS) in 2002, Middle East respiratory syndrome (MERS) in 2012, and coronavirus disease 2019 (COVID-19) in 2019.

18 Oct 2020

WHO study finds Remdesivir and other repurposed drugs ineffective in COVID-19

A large-scale randomized trial has recently been conducted by the World Health Organization (WHO) to evaluate the efficacy of four repurposed antiviral medicines, including Remdesivir, Hydroxychloroquine, Lopinavir, and Interferon, currently used to treat hospitalized coronavirus disease 2019 (COVID-19) patients.

18 Oct 2020

Antibody levels drop rapidly in recovering COVID-19 patients, shows study

In the absence of approved, effective treatments for COVID-19, some hospitals have been treating patients with severe COVID symptoms with blood plasma from recovering patients.

16 Oct 2020

Control trial proves effectiveness of repurposed drugs for COVID-19 treatment

In just six months, the world's largest randomized control trial on COVID-19 therapeutics has generated conclusive evidence on the effectiveness of repurposed drugs for the treatment of COVID-19.

16 Oct 2020

New article explores the endemic potential of COVID-19 virus

A new article by Columbia Mailman School researchers Jeffrey Shaman and Marta Galanti explores the potential for the COVID-19 virus to become endemic, a regular feature producing recurring outbreaks in humans.

16 Oct 2020

Rapid development of functionally diverse SARS-COV-2 mouse monoclonal antibodies

Now, a recent study published on the preprint server bioRxiv in October 2020 reports the development of a rapid process for generating high-affinity mouse mAbs, and their functional attributes.

16 Oct 2020

High-titer convalescent plasma reduced COVID-19 symptom severity in green monkeys

As scientists scramble to find effective vaccines and antivirals for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a recent study published on the preprint server bioRxiv in October 2020 reports that the use of convalescent plasma to treat COVID-19 disease early in the course of the illness may be among the best available strategies at present.

16 Oct 2020

Synthetic signals could help control tissue regeneration, guide cellular therapies

For a tiny embryo to develop into an adult organism, its cells must develop in precise patterns and interact with their neighbors in carefully orchestrated ways.

16 Oct 2020

Sanofi Translate Bio MRT5500 COVID-19 vaccine shows promise in preclinical trials

The COVID-19 pandemic is threatening to come back in greater intensity during the winter and fall. Faced with this threat, vaccine development efforts are entering a phase of renewed focus, attempting to identify antigens capable of eliciting protective levels of neutralizing antibodies. A new study published on the preprint server bioRxiv* in October 2020 reports on a novel mRNA vaccine candidate's performance in two animal models.

16 Oct 2020

Scientists engineer powerful novel anti-microbial molecules from wasp venom

Now, a team of scientists in the Perelman School of Medicine at the University of Pennsylvania has engineered potent novel anti-microbial molecules from toxic proteins found in wasp venom. The researchers believe that the discovery holds promise in fighting the increasing number of antibiotic-resistant bacteria, that cause serious illness.

15 Oct 2020

Previous infections with seasonal coronaviruses might protect against SARS-CoV-2

Seasonal coronaviruses, which generally cause mild respiratory illness and symptoms of the common cold, belong to the same viral family as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes COVID-19.

15 Oct 2020

Obese persons have greater risk of developing severe COVID-19

The probability that an obese person will develop severe COVID-19 is high regardless of age, sex, ethnicity, and the presence of co-morbidities such as diabetes, high blood pressure, and heart or lung disease, according to a study by Brazilian researchers published in Obesity Research & Clinical Practice.

15 Oct 2020

Capillary blood microsampling could prove a breakthrough in SARS-CoV-2 serosurveillance

As COVID-19 seems to be making a comeback in many areas of the world, including Japan, a new study published on the preprint server medRxiv in October 2020 shows the relevance of microsamples of blood in serosurveillance of this disease.

15 Oct 2020

Rapid SARS‐CoV‐2 IgM‐IgG combined antibody test

A recent study published on the preprint server medRxiv in October 2020 reports a new diagnostic test for SARS-CoV-2 based on the detection of antibodies.

15 Oct 2020

Human bivalent SARS-CoV-2 neutralizing antibodies more potent

A recent study published on the preprint server bioRxiv in October 2020 reports more effective viral neutralization by bivalent anti-spike antibodies. This could promote the development of better therapeutics and vaccines.

15 Oct 2020

Certain live-attenuated vaccines can prevent severe complications of COVID-19

COVID-19 continues to wreak havoc globally, with over one million deaths to date. Yet what if an existing vaccine could make COVID-19 less deadly? A study just published put the theory to test, with promising results.

15 Oct 2020

The COVID-19 vaccine pipeline

Researchers from Mayo Clinic, United States of America, have reviewed the immunity developed against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19 disease.

14 Oct 2020

FDA approves Regeneron antibody drug as first treatment for Ebola virus

Today, the U.S. Food and Drug Administration approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three monoclonal antibodies, as the first FDA-approved treatment for Zaire ebolavirus (Ebola virus) infection in adult and pediatric patients.

14 Oct 2020